Role for TNF in atherosclerosis? Lessons from autoimmune disease

Nature Reviews Cardiology

Volumn 6, Issue 6, 2009, Pages 410-417

  McKellar, Gayle E ^a   McCarey, David W ^a   Sattar, Naveed ^b   McInnes, Iain B ^c  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTACOID; CARDIOVASCULAR AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTERY; ATHEROSCLEROSIS; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG EFFECT; ELASTICITY; HEART FAILURE; HUMAN; IMMUNOLOGY; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM; OBESITY; PATHOPHYSIOLOGY; REGISTER; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIES; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; ELASTICITY; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPID METABOLISM; OBESITY; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69249222895     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.57     Document Type: Article

References (75)

1. Mcinnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429-442 (2007).
2. Feldmann, M., Brennan, F. M. & Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-40 (1996).
3. Zhang, H. Role of TNF-alpha in vascular dysfunction. Clin. Sci. (Lond.). 116, 219-230 (2009).
4. Grisar, J. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumournecrosis factor and glucocorticoid therapy. Ann. Rheum. Dis. 66, 1284-1288 (2007).
5. Quinn, K., Henriques, M., Parker, T., Slutsky, A. S. & Zhang, H. Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 295, H1817-H1824 (2008).
6. Zhao, S. P & Dong, S. Z. Effect of tumor necrosis factor alpha on cholesterol efflux in adipocytes. Clin. Chim. Acta 389, 67-71 (2008).
7. Nguyen, M. T. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J. Biol. Chem. 280, 35361-35371 (2005).
8. Van Doornum, S., McColl, G. & Wicks, I. P Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46, 862-873 (2002).
9. Capell, H., McCarey, D., Madhok, R. & Hampson, R. “5D” Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy. J. Rheumatol. 29, 2099-2105 (2002).
10. Wallberg-Jonsson, S., Ohman, M. L. & Dahlqvist, S. R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445-451 (1997).
11. del Rincon, I. D., Williams, K., Stern, M. P, Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737-2745 (2001).
12. Gonzalez-Gay, M. A. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 57, 125-132 (2007).
13. Sattar, N., McCarey, D. W., Capell, H. & Mcinnes, I. B. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957-2963 (2003).
14. Avina-Zubieta, J. A. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 59, 1690-1697 (2008).
15. Hannawi, S., Haluska, B., Marwick, T. H. & Thomas, R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res. Ther. 9, R116 (2007).
16. Hahn, B. H., Grossman, J., Ansell, B. J., Skaggs, B. J. & McMahon, M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 10, 213 (2008).
17. Cheng, X. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol. 127, 89-97 (2008).
18. Pasceri, V & Yeh, E. T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100, 2124-2126 (1999).
19. Feldmann, M., Brennan, F. M. & Maini, R. N. Rheumatoid arthritis. Cell 85, 307-310 (1996).
20. Brennan, F. M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244-247 (1989).
21. Keffer, J. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
22. Williams, R. O., Feldmann, M. & Maini, R. N. Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 89, 9784-9788 (1992).
23. Maini, R. infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase iii trial. ATTRACT Study Group. Lancet 354, 1932-1939 (1999).
24. Feldmann, M. & Maini, R. N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196 (2001).
25. Bathon, J. M. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
26. Weinblatt, M. E. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35-45 (2003).
27. Hansel, S., Lassig, G., Pistrosch, F. & Passauer, J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170, 177-180 (2003).
28. Booth, A. D. infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109, 1718-1723 (2004).
29. Gonzalez-Juanatey, C. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 57,287-293 (2007).
30. Hurlimann, D. Anti-tumor necrosis factor- alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187 (2002).
31. irace, C. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 177, 113-118 (2004).
32. Laurent, S. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37, 1236-1241 (2001).
33. Wilkinson, I. B. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler. Thromb. Vasc. Biol. 22, 147-152 (2002).
34. Weber, T. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 109, 184-189 (2004).
35. Maki-Petaja, K. M. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 114, 1185-1192 (2006).
36. Avalos, I. increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis. J. Rheumatol. 34, 2388-2394 (2007).
37. Van Doornum, S., McColl, G. & Wicks, i. P Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 44, 1428-1432 (2005).
38. Van Doornum, S., McColl, G. & Wicks, i. P Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 63, 1571-1575 (2004).
39. Jonsson, S. W. increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J. Rheumatol. 28, 2597-2602 (2001).
40. Gonzalez-Juanatey, C. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 57, 1074-1780 (2007).
41. Gonzalez-Juanatey, C., Llorca, J., Garcia- Porrua, C., Martin, J. & Gonzalez-Gay, M. A. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum. 55, 150-153 (2006).
42. Del Porto, F. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 46, 1111-1115 (2007).
43. Hotamisligil, G. S., Arner, P, Caro, J. F., Atkinson, R. L. & Spiegelman, B. M. increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95, 2409-2415 (1995).
44. Dandona, P Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 83, 2907-2910 (1998).
45. Gonzalez-Gay, M. A. influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24, 373-379 (2006).
46. Yazdani-Biuki, B. improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur. J. Clin. Invest. 34, 641-642 (2004).
47. Kiortsis, D. N., Mavridis, A. K., Vasakos, S., Nikas, S. N. & Drosos, A. A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64, 765-766 (2005).
48. Sarwar, N., Sattar, N., Gudnason, V. & Danesh, J. Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur. Heart J. 28, 2491-2497 (2007).
49. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association.
50. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (Suppl 5), v1-v52 (2005).
51. Allanore, Y, Kahan, A., Sellam, J., Ekindjian, O. G. & Borderie, D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin. Chim. Acta 365, 143-148 (2006).
52. Vis, M. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol. 32, 252-255 (2005).
53. Popa, C. influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64, 303-305 (2005).
54. Sattar, N. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo- controlled study. Arthritis Rheum. 56, 831-839 (2007).
55. Peters, M. J. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann. Rheum. Dis. 66, 958-961 (2007).
56. Popa, C. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 66, 1503-1507 (2007).
57. Rossner, S. & Lofmark, C. Dyslipoproteinaemia in patients with active, chronic polyarthritis. A study on serum lipoproteins and triglyceride clearance (intravenous fat tolerance test). Atherosclerosis 28, 41-52 (1977).
58. Vermont, C. L. Serum lipids and disease severity in children with severe meningococcal sepsis. Crit. Care Med. 33, 1610-1615 (2005).
59. Alexopoulos, C. G., Pournaras, S., Vaslamatzis, M., Avgerinos, A. & Raptis, S. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother. Pharmacol. 30, 412-16 (1992).
60. Akgun, S., Ertel, N. H., Mosenthal, A. & Oser, W. Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response. J. Lab. Clin. Med. 131, 103-108 (1998).
61. Popa, C. Anti-inflammatory therapy with TNFa inhibitors improves HDL-cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. doi:10.1136/ ard.2008.092171 (2008).
62. Jick, S. S., Choi, H., Li, L., Mcinnes, i. B. & Sattar, N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann. Rheum. Dis. 68, 546-551 (2008).
63. Listing, J. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 58, 667-677 (2008).
64. Jacobsson, L. T. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213-1218 (2005).
65. Dixon, W. G. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905-2912 (2007).
66. Dixon, W. G. Rates of myocardial infarction and cerebrovascular accident are reduced in patients with rheumatoid arthritis treated with anti-TNF therapy compared to those treated with traditional DMARDS: results from the BSR biologics register. Ann. Rheum. Dis. 65 (Suppl II), 109 (2006).
67. Mann, D. L. inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91, 988-998 (2002).
68. Levine, B., Kalman, J., Mayer, L., Fillit, H. M. & Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323,236-241 (1990).
69. Chung, E. S. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140 (2003).
70. Mann, D. L. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602 (2004).
71. Kwon, H. J., Cote, T. R., Cuffe, M. S., Kramer, J. M. & Braun, M. M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138, 807-811 (2003).
72. Nicola, P. J. The risk of congestive heart failure in rheumatoid arthritis: a population- based study over 46 years. Arthritis Rheum. 52, 412-20 (2005).
73. Smolen, J. S. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTiON study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987-997 (2008).
74. Choy, E. & Sattar, N. interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 68, 460-469 (2009).
75. Gonzalez-Juanatey, C. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 59, 1821-1824 (2008).